SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 70 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $97,000 | -88.2% | 81,891 | -55.4% | 0.00% | -100.0% |
| Q3 2021 | $820,000 | -49.2% | 183,451 | -38.1% | 0.00% | -57.1% |
| Q2 2021 | $1,615,000 | +220.4% | 296,405 | +538.5% | 0.01% | +133.3% |
| Q4 2020 | $504,000 | +93.1% | 46,423 | +89.8% | 0.00% | +50.0% |
| Q2 2020 | $261,000 | +53.5% | 24,458 | +86.7% | 0.00% | -71.4% |
| Q1 2018 | $170,000 | – | 13,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |